c19development

Monday, August 31, 2020 SPRINGDALE, AR, August 31, 2020 – NOWDiagnostics, Inc. announced today it is working with BARDA, the Biomedical Advanced Research and Development Authority arm of the U.S. Department of Health and Human Services, to develop a serological test for SARS-CoV-2 antibodies that can be used across a variety of health care settings—from clinics

ADEXUSDx COVID-19 Test receives Conformité Européene (CE) mark approval We are proud to announce that our ADEXUSDx COVID-19 antibody test has received Conformité Européene (CE) mark approval across 28 countries in the EU. With CE approval, our antibody test will be available in a variety of healthcare centers such as clinics and hospital emergency rooms.

Introducing the ADEXUSDx COVID-19 Test At NOWDiagnostics, we’re always looking for ways to respond to community needs. Our new, rapid ADEXUSDx COVID-19 serology antibody test will be essential to America’s recovery from COVID-19, as we believe it can assist with vaccine development and contact tracing. Interested in learning more? You can read the full article

NOWDx seeks FDA Emergency Use Authorization (EUA) for COVID-19 Test The ADEXUSDx® COVID-19 Test is a rapid serology test that detects total antibodies to SARS-CoV-2. It provides in-field, lab accurate results within 15 minutes, using as little as a drop of blood. The test does not require buffers or reagents, lab equipment, refrigeration, or in demand ancillary